Back to Newsroom

StemCells, Inc. Interim Trial Data Show Motor Improvement in Patients With Cervical Spinal Cord Injury

NEWARK, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) — StemCells, Inc.(NASDAQ:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today announced that the six-month interim results for the first cohort in its ongoing Phase II Pathway™ Study in cervical spinal cord injury (SCI) showed motor improvements in both strength and function. The assessment of motor function involved using tests of dexterity.

Click here to read the full release